Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.25 - $2.75 $4,881 - $10,738
3,905 Added 139.46%
6,705 $10,000
Q3 2023

Nov 14, 2023

BUY
$2.66 - $4.33 $7,448 - $12,124
2,800 New
2,800 $8,000
Q2 2020

Aug 14, 2020

SELL
$4.59 - $8.96 $206 - $403
-45 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$2.65 - $6.08 $119 - $273
45 New
45 $0
Q2 2019

Aug 14, 2019

SELL
$3.06 - $51.61 $27,888 - $470,373
-9,114 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$31.16 - $48.62 $283,992 - $443,122
9,114 New
9,114 $344,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $77.4M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.